Baseline Characteristics at Initiation of Tocilizumab Therapy in Patients Completing 6 Months of Treatment.

<p>Results are presented as the mean ± standard deviation, median (minimum, maximum), or number of cases with percentages. CDAI: clinical disease activity index; CI: confidence interval; d: difference; LEF: leflunomide; MTX: methotrexate; SDAI: simplified disease activity index.</p><p>Baseline Characteristics at Initiation of Tocilizumab Therapy in Patients Completing 6 Months of Treatment.</p

Genotype frequencies of the <i>FCGR2A</i> polymorphism rs1801274 in anti-CCP positive RA patients according to the clinical response at week 12.

<p>^aFisher's exact test; ANTI-CCP: anti-citrullinated protein antibodies; OR: Odds ratio using allele G as reference.</p><p>Genotype frequencies of the <i>FCGR2A</i> polymorphism rs1801274 in anti-CCP positive RA patients according to the clinical response at week 12.</p

Genotype frequencies of the <i>FCGR2A</i> polymorphism rs1801274 according to the clinical response at week 12.

<p>^aFisher's exact test; OR: Odds ratio using allele G as reference.</p><p>Genotype frequencies of the <i>FCGR2A</i> polymorphism rs1801274 according to the clinical response at week 12.</p

Epidemiological and Clinical Features of the Patient Study Cohort.

<p>Except where indicated otherwise, values are the mean ±SD. RF: rheumatoid factor; Anti-CCP: anti-citrullinated protein antibodies; DMARDs: disease-modifying antirheumatic drugs; ΔDAS28; delta DAS28 (DAS28 baseline—DAS28 endpoint); EULAR: European League Against Rheumatism response, where Good and Moderate EULAR responders were merged into a single Responder category.</p><p>Epidemiological and Clinical Features of the Patient Study Cohort.</p

Additional file 1: Table S1. of Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis

Presenting the association of IL6R locus SNPs with joint damage in the discovery stage under alternative genetic models, Table S2. Presenting the association of IL6R locus SNPs with joint damage in the discovery stage according to ACPA or RF status, and Table S3. Presenting the enhancer histone marks associated with the IL6R rs4845618 SNP identified in 111 reference epigenomes from the Epigenome Roadmap Project